- Wall Street in mixed mood at the start of Tuesday's session
- Investors' attention turns to quarterly results
- Goldman Sachs, UnitedHealth and Bank of America, among others, showed their results
Markets in the US open Tuesday's cash session in a mixed mood. Five minutes after the Wall Street open, the Nasdaq is gaining 0.18%, while the S&P500 is adding 0.08%. Investor attention today is focused on corporate news.
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile appCurrent volatility observed on Wall Street. Source: xStation
US100
The Nasdaq-100 index, represented by the US100 contract is trading flat today relative to the close of Monday's trading. However, the index continues to maintain a dynamic uptrend all the time, which with its range oscillates not far from new historical highs. From a technical perspective, it seems that the support set by the 50-day EMA (blue curve on the chart) and the psychological level of $20,000 may be key to sustaining the increases.
Source: xStation 5
Corporate news
Bank of America (BAC.US) is up about 2% after its Wall Street operations performed better than expected, and the company benefited from market volatility. Net interest income beat analysts' estimates.
BANK'S Q3 RESULTS:
- Net interest income $13.97 billion, estimates $13.9 billion
- FICC trading income $2.94 billion, estimate $2.77 billion
- Share trading revenue $2.00 billion, estimate $1.81 billion
- Total wealth and investment management revenue $5.76 billion, estimate $5.63 billion
- Net interest expense income $25.35 billion, estimate $25.27 billion
- Provision for credit losses $1.54 billion, estimate $1.53 billion
- EPS 81c vs. 90c y/y
- Return on average equity 9.44%, estimated 9.01%
- Basel III Tier 1 capital ratio fully implemented, advanced approach 13.5%, estimated 13.5%
- Standard CET1 ratio 11.8%, estimated 11.9%
- Payroll costs $9.92 billion, estimate $9.9 billion
- Investment banking revenues $1.40 billion, estimate $1.24 billion
- Advisory fees $387 million, estimate $341.8 million
- Revenue from debt issuance $780 million, estimate $669 million
- Capital issue proceeds $270 million, estimate $258.4 million
- Net write-downs $1.53 billion, estimate $1.5 billion
- Loans $1.08 trillion, estimate $1.07 trillion
- Total deposits $1.93 trillion, estimate $1.93 trillion
- Efficiency ratio of 65%
- Non-interest expense $16.48 billion, estimate $16.49 billion
Goldman Sachs (GS.US) grows 2%. The bank's profit rose 45% in the third quarter, thanks to a surprising increase in income from stock trading and a resurgent investment banking business.
THIRD QUARTER RESULTS
- Net profit of $12.70 billion, up an estimated $11.77 billion
- FICC sales and trading income $2.96 billion, estimate $2.96 billion
- Global Banking & Markets net income $8.55 billion, +6.8% y/y, estimate $7.65 billion
- Investment banking revenue $1.86 billion, +20% y/y, estimate $1.68 billion
- Revenue from equity sales and trading $3.50 billion, +18% y/y, $2.95 billion estimate
- Advisory revenues $875 million, +5.3% y/y, estimate $757.5 million
- Revenue from equity issuance $385 million, +25% y/y, estimate $359.6 million
- Debt issue proceeds $605 million, +46% y/y, estimate $567.9 million
- EPS of $8.40 vs. $5.47 y/y
- Net interest income $2.62 billion, +70% y/y, estimated $1.84 billion
- Platform Solutions pre-tax loss $559 million, estimated loss $302.7 million
- Total deposits $445 billion, +2.8% q/q.
- Provision for credit losses $397 million vs. $7 million y/y, estimate $411.9 million
- Total operating expenses $8.32 billion, -8.2% y/y, estimate $8.11 billion
- Payroll costs $4.12 billion, -1.6% y/y, estimate $3.89 billion
- Annual ROE +10.4%, estimated +8.73%
- Return on equity +11.1%, estimated +9.44%
- Standard CET1 ratio 14.6%, estimated 14.7%
- Book value per share $332.96, compared with $313.83 y/y
- Efficiency ratio 65.5%, estimated 68.5%
- Assets under management $3.10 trillion, +16% y/y, $2.99 trillion estimate
UnitedHealth (UNH.US) is down 9% after the company lowered the top end of its forecast, a rare move for an insurance giant that has often withstood pressures that hurt its competitors.
ANNUAL FORECAST
Adjusted earnings per share forecast $27.50 to $27.75, previously estimated at $27.50 to $28, estimated at $27.68
Q3 RESULTS
- Adjusted earnings per share $7.15 vs. $6.56 y/y, estimated $6.99
- EPS $6.51 vs. $6.24 y/y
- Revenue $100.82 billion, +9.2% y/y, estimated $99.16 billion
- UnitedHealthcare segment revenue $74.9 billion, +7.2% y/y, estimated $73.65 billion
- Optum revenues $63.9 billion, +13% y/y
- OptumRx revenues $34.21 billion, +19% y/y, estimated $32.21 billion
- OptumHealth revenues $25.92 billion, +8.6% y/y, $27.48 billion estimate
- OptumInsight revenue $4.93 billion, -0.9% y/y, $4.99 billion estimate
- Medical care ratio 85.2% vs. 82.3% y/y, estimated 84.4%
- Operating expense ratio 13.2% vs. 15% y/y, estimate 13.5%
ANALYSTS' RECOMMENDATION
- Blackstone Inc (BX.US): JPMorgan raises target price to $125 from $109, expecting the asset manager's latest fundraising supercycle to drive earnings growth.
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.